Bliss GVS Pharma Reports Unaudited Q1 Financial Results; Approves Director Appointment
Bliss GVS Pharma Limited released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's Board of Directors reviewed and approved the interim results during a meeting held on August 12, 2026. Additionally, the Board considered the draft of a postal ballot notice regarding the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director.The financial performance data for the quarter was presented along with a Limited Review Report from the Auditors.
Unaudited Standalone Financial Results Summary
The following table summarizes key metrics from the unaudited standalone results:| Particulars | Quarter Ended June 30, 2026 | Year Ended March 31, 2026 (Audited) |
|---|---|---|
| Revenue from Operations | 22,158.51 | 72,980.76 |
| Total Income | 23,034.67 | 77,352.63 |
| Total Expenses | 17,913.75 | 63,790.62 |
| Profit before Tax (V-VI) | 5,120.92 | 13,346.46 |
| Net Profit for the Period | 3,861.77 | 9,687.44 |
Consolidated Financial Results Overview
The consolidated figures reflect the performance of the Group during the quarter ended June 30, 2026:| Particulars | Quarter Ended June 30, 2026 | Year Ended March 31, 2026 (Audited) |
|---|---|---|
| Revenue from Operations | 28,557.56 | 92,711.28 |
| Total Income | 29,517.53 | 100,064.26 |
| Total Expenses | 21,969.22 | 80,856.63 |
| Net Profit for the Period | 7,548.31 | 19,207.63 |
The company noted that its business falls within a single operating segment: "Pharmaceutical and Healthcare," and therefore no segment information is disclosed.
Operational Highlights and Review Findings
The results are subject to a limited review by the statutory auditors, who have issued reports with an unmodified conclusion. The figures for the quarter ended March 31, 2026, in both standalone and consolidated statements are presented as balancing figures between audited full financial year data and previous unaudited year to date figures that were reviewed.The results also reflect the recording of an incremental expense amounting to approximately 215.55 Lakh and 248.71 Lakh in standalone and consolidated financials, respectively, for the year ended March 31, 2026, representing a reassessment of employee benefit obligations following the implementation of New Labour Codes with effect from November 21, 2025, recognized as Exceptional Items.
The review conducted by Chartered Accountants highlighted that nothing came to their attention that caused them to believe that the accompanying statements contained any material misstatement or failed to disclose required information.
BLISSGVS Stock Price Movement
On Wednesday, shares of Bliss GVS Pharma Limited slipped by 0.82%, settling at ₹489.55 in market action. The stock traded on a volume of 277,203 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.